SciGen Ltd, a biotechnology company, develops, manufactures, and markets recombinant human health care biotechnology derived products in the areas of endocrinology, gastroenterology, immunology, paediatrics, neurology, and oncology care worldwide. It offers SciLin, a recombinant human insulin expressed in E.coli for treating diabetes; SciTropin A, a human growth hormone synthesized in E.coli cells; and SciLocyte, a recombinant granulocyte colony stimulating factor used to prevent and treat the decrease of white blood cells resulting from chemotherapy. The company also provides Heri Injection used to treat malignant tumors, hepatitis, and other immunodeficiency diseases; Zinc – S injection for parenteral nutrition; and ZINC –I syrup for treating and preventing zinc deficiency, psoriasis, and diarrhea. In addition, it offers Dipherelin, a prolonged release injection for the treatment of central precocious puberty, prostate cancer and endometriosis; Durolane, an original single hyaluronic acid stabilized injection for osteoarthritis pain relief; SciTrace 5 and NeoTrace 4 injection for use as an additive for total parenteral nutrition; and Insupen needles. Further, the company provides Al-Sense, an amniotic fluid leak detection test for continual reassurance; Gensupen, an automatic delivery system for insulin; and Insupen needles. Additionally, the company in-licenses and distributes pharmaceutical products and medical devices. It sells its products in Thailand, Philippines, Australia, Korea, Pakistan, Vietnam, and others. SciGen Ltd was founded in 1988 and is headquartered in Singapore. SciGen Ltd is a former subsidiary of Bioton S.A. As of August 7, 2018, SciGen Ltd operates as a subsidiary of YiFan International Pharmaceutical Co., Limited.